arrow
X

Xavier González

solti cancer research group
H指数:22
被引数:2,197

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)

talimogene laherparepvec和atezolizumab在HER2阴性乳腺癌新辅助化疗后的应用:一项窗口期II期试验(SOLTI-1503 PROMETEO)

2026-02-160
OA
Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis

内分泌为基础的策略在激素受体阳性晚期乳腺癌生物标志物选择亚组中CDK4/6抑制剂后的应用:一项系统评价和网络Meta分析

2025-12-030
PRE
A Retrospective Observational Study of Extended Adjuvant Neratinib for HER2-Positive Early-Stage Breast Cancer in a European Early Access Program

一项在欧洲早期准入计划中对HER2阳性早期乳腺癌进行延长辅助尼妥珠单抗治疗的回顾性观察研究

2025-10-290
OA
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial

PD1疗法在PD1高表达mRNA肿瘤中的疗效:SOLTI-1904 ACROPOLI II期试验中队列1和队列2的结果

2025-09-300
OAAI
Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial

帕博西利和曲妥珠单抗用于HER2阳性转移性乳腺癌:SOLTI-1303-PATRICIA试验A组和B组的最终总生存结果

2025-09-010
OAAI
Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial

预防曲拉鲁单抗govitecan相关中性粒细胞减少症和腹泻在HER2阴性晚期乳腺癌患者中的效果(PRIMED):一项开放标签、单臂、Ⅱ期临床试验

2025-07-010
PRE
Regulation of Caenorhabditis elegans HLH-30 subcellular localization dynamics: Evidence for a redox-dependent mechanism

HLH-30亚细胞定位动力学调节秀丽隐杆线虫: 氧化还原依赖性机制的证据

2024-10-010
OAAI
Characterizing Immune Infiltration in Metastatic Hormone Receptor-Positive/HER2Negative Breast Cancer: A Comprehensive Translational Analysis from four SOLTI Clinical Trials
2024-05-020
PRE
SOLTI-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC)
2024-05-020
PRE
Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial
2024-05-023
PRE
A phase 2 randomized pre-operative,window of opportunity trial investigating the effect of elacestrant with/without triptorelin in premenopausal patients with HR+/HER2-breast cancer-SOLTI2104-PremiERe trial
2024-05-020
PRE
Targeting PAM50 HER2-Enriched intrinsic subtype with enzalutamide in hormone receptor- positive/HER2-negative (HR+/HER2-) advanced breast cancer: results of the SOLTI-1502 ARIANNA trial
2024-05-020
PRE
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy
2024-03-063
OAAI
Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types

跨癌症类型的具有和不具有三级淋巴样结构的肿瘤中的基因表达谱

2023-10-010
PRE
Tumor-infiltrating lymphocites and gene expression across multiple cancer-types: A translational analysis from the SOLTI-1904-ACROPOLI study

肿瘤浸润性淋巴细胞和多种癌症类型的基因表达: 来自SOLTI-1904-ACROPOLI研究的翻译分析

2023-10-010
PRE
Cell-Cycle Inhibition and Immune Microenvironment in HR+/HER2-Breast Cancer During and After preoperative ribociclib and letrozole vesus chemotherapy: A correlative analysis of the 1402-SOLTI/CORALLEEN phase 2 trial
2023-03-010
PRE
Elacestrant in postmenopausal women with estrogen receptor positive and HER2-negative early breast cancer: primary efficacy and safety analysis of the preoperative, window of opportunity SOLTI-1905-ELIPSE trial
2023-03-016
PRE
Primary results of SOLTI-1503 PROMETEO phase 2 trial of Combination of Talimogene Laherparepvec (T-VEC) with Atezolizumab in patients with residual breast cancer after standard neoadjuvant multi-agent chemotherapy
2023-03-011
PRE